| Ticker: ENMD | 9610 Medical Center Drive, Suite 200 | |
| Exchange: NASDAQ-National Market | Rockville, Maryland 20850 | |
| Industry: Service | (301) 217-9858 |
| Type of Shares: | Common Shares | Filing Date: | 4/12/96 | |
| U.S. Shares: | 3,200,000 | Offer Date: | 6/11/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $14.00 - $16.00 | |
| Primary Shares: | 3,200,000 | Offer Price: | $15.00 | |
| Secondary Shares: | 0 | Gross Spread: | $1.12 | |
| Offering Amount: | $48,000,000 | Selling: | $0.67 | |
| Expenses: | $1,000,000 | Reallowance: | $0.10 | |
| Shares Out After: | 11,993,912 |
| Manager | Tier | Phone |
| Allen & Company Incorporated | Lead Manager | (212) 832-8000 |
| Dillon, Read & Co. Inc. | Co-manager | (212) 906-7000 |
| Volpe, Welty & Company | Co-manager | (415) 956-8120 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $0.71 | $1.09 | $0.00 | Assets: | $8.61 |
| Net Income: | -$7.71 | -$1.68 | -$2.05 | Liabilities: | $6.55 |
| EPS: | -$0.83 | -$0.18 | Equity: | $2.05 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is engaged primarily in the research and development of biopharmaceutical products that address the role of blood and blood vessels in the prevention and treatment of a broad range of diseases. The company's core technologies include i) an antiangiogenesis program focused on the development of proprietary products intended to inhibit the abnormal growth of new blood vessels associated with cancer and certain causes of blindness and ii) a blood cell permeation device designed to enhance the ability of red blood cells to deliver oxygen to organs and tissues and which may also be used to deliver drugs, genes or other therapeutic agents that otherwise would not readily diffuse through blood cell membranes. Angiogenesis is the fundamental process by which new blood vessels are formed and primarily occurs during the first three months of embryonic development. Except for wound healing and certain reproductive processes in women, angiogenesis is otherwise generally associated with several diseases, including cancer and certain causes of blindness. |
| Use of Proceeds |
| The proceeds from the offering will be used for research and development, working capital and for general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.